Effect of Time and Titer in Convalescent Plasma Therapy for COVID-19

Overview

Journal iScience

Publisher Cell Press

Date 2021 Jul 28

PMID 34316549

Citations 11

Authors

Paola de Candia

Francesco Prattichizzo

Silvia Garavelli

Rosalba La Grotta

Annunziata De Rosa

Agostina Pontarelli

Roberto Parrella

Antonio Ceriello

Giuseppe Matarese

Affiliations

Soon will be listed here.

Abstract

The clinical benefit of convalescent plasma (CP) for patients with coronavirus disease (COVID)-19 is still debated. In this systematic review and meta-analysis, we selected 10 randomized clinical trials (RCTs) and 15 non-randomized studies (total number of patients = 22,591) of CP treatment and evaluated two different scenarios: (1) disease stage of plasma recipients and (2) donated plasma antibody titer, considering all-cause mortality at the latest follow-up. Our results show that, when provided at early stages of the disease, CP significantly reduced mortality: risk ratio (RR) 0.72 (0.68, 0.77), p < 0.00001, while provided in severe or critical conditions, it did not (RR: 0.94 [0.86, 1.04], p = 0.22). On the other hand, the benefit on mortality was not increased by using plasma with a high-antibody titer compared with unselected plasma. This meta-analysis might promote CP usage in patients with early-stage COVID-19 in further RCTs to maximize its benefit in decreasing mortality, especially in less affluent countries.

Citing Articles

Early, very high-titre convalescent plasma therapy in clinically vulnerable individuals with mild COVID-19 (COVIC-19): protocol for a randomised, open-label trial.

Desmarets M, Hoffmann S, Vauchy C, Rijnders B, Toussirot E, Durrbach A BMJ Open. 2023; 13(4):e071277.

PMID: 37105693 PMC: 10151238. DOI: 10.1136/bmjopen-2022-071277.

Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial.

Denkinger C, Janssen M, Schakel U, Gall J, Leo A, Stelmach P Nat Cancer. 2022; 4(1):96-107.

PMID: 36581734 PMC: 9886549. DOI: 10.1038/s43018-022-00503-w.

One-year follow-up of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patients.

Korper S, Gruner B, Zickler D, Wiesmann T, Wuchter P, Blasczyk R J Clin Invest. 2022; 132(24).

PMID: 36326824 PMC: 9753994. DOI: 10.1172/JCI163657.

A comprehensive insight into current control of COVID-19: Immunogenicity, vaccination, and treatment.

Mohamed Y, El-Maradny Y, Saleh A, Nayl A, El-Gendi H, El-Fakharany E Biomed Pharmacother. 2022; 153:113499.

PMID: 36076589 PMC: 9343749. DOI: 10.1016/j.biopha.2022.113499.

Repertoires of SARS-CoV-2 epitopes targeted by antibodies vary according to severity of COVID-19.

Gregory D, Vannier A, Duey A, Roady T, Dzeng R, Pavlovic M Virulence. 2022; 13(1):890-902.

PMID: 35587156 PMC: 9122311. DOI: 10.1080/21505594.2022.2073025.

References

Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. PMC: 7095418. DOI: 10.1038/s41586-020-2012-7. View

Wibmer C, Ayres F, Hermanus T, Madzivhandila M, Kgagudi P, Oosthuysen B . SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nat Med. 2021; 27(4):622-625. DOI: 10.1038/s41591-021-01285-x. View

Boonyaratanakornkit J, Morishima C, Selke S, Zamora D, McGuffin S, Shapiro A . Clinical, laboratory, and temporal predictors of neutralizing antibodies against SARS-CoV-2 among COVID-19 convalescent plasma donor candidates. J Clin Invest. 2020; 131(3). PMC: 7843229. DOI: 10.1172/JCI144930. View

Thompson M, Henderson J, Shah P, Rubinstein S, Joyner M, Choueiri T . Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19. JAMA Oncol. 2021; . PMC: 8377563. DOI: 10.1001/jamaoncol.2021.1799. View

Davis M, McCreary E, Pogue J . That Escalated Quickly: Remdesivir's Place in Therapy for COVID-19. Infect Dis Ther. 2020; 9(3):525-536. PMC: 7348566. DOI: 10.1007/s40121-020-00318-1. View

Wang P, Nair M, Liu L, Iketani S, Luo Y, Guo Y . Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature. 2021; 593(7857):130-135. DOI: 10.1038/s41586-021-03398-2. View

Cohen M . Monoclonal Antibodies to Disrupt Progression of Early Covid-19 Infection. N Engl J Med. 2021; 384(3):289-291. PMC: 7844860. DOI: 10.1056/NEJMe2034495. View

Horby P, Lim W, Emberson J, Mafham M, Bell J, Linsell L . Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2020; 384(8):693-704. PMC: 7383595. DOI: 10.1056/NEJMoa2021436. View

Lu R, Zhao X, Li J, Niu P, Yang B, Wu H . Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020; 395(10224):565-574. PMC: 7159086. DOI: 10.1016/S0140-6736(20)30251-8. View

10.

Xia X, Li K, Wu L, Wang Z, Zhu M, Huang B . Improved clinical symptoms and mortality among patients with severe or critical COVID-19 after convalescent plasma transfusion. Blood. 2020; 136(6):755-759. PMC: 7414593. DOI: 10.1182/blood.2020007079. View

11.

Skrip L, Derra K, Kabore M, Noori N, Gansane A, Valea I . Clinical management and mortality among COVID-19 cases in sub-Saharan Africa: A retrospective study from Burkina Faso and simulated case analysis. Int J Infect Dis. 2020; 101:194-200. PMC: 7518969. DOI: 10.1016/j.ijid.2020.09.1432. View

12.

Balcells M, Rojas L, Le Corre N, Martinez-Valdebenito C, Ceballos M, Ferres M . Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial. PLoS Med. 2021; 18(3):e1003415. PMC: 7929568. DOI: 10.1371/journal.pmed.1003415. View

13.

Liu S, Lin H, Baine I, Wajnberg A, Gumprecht J, Rahman F . Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study. Nat Med. 2020; 26(11):1708-1713. DOI: 10.1038/s41591-020-1088-9. View

14.

Rasheed A, Fatak D, Hashim H, Maulood M, Kabah K, Almusawi Y . The therapeutic potential of convalescent plasma therapy on treating critically-ill COVID-19 patients residing in respiratory care units in hospitals in Baghdad, Iraq. Infez Med. 2020; 28(3):357-366. View

15.

Cheng Y, Wong R, Soo Y, Wong W, Lee C, Ng M . Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2004; 24(1):44-6. PMC: 7088355. DOI: 10.1007/s10096-004-1271-9. View

16.

Cele S, Gazy I, Jackson L, Hwa S, Tegally H, Lustig G . Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma. Nature. 2021; 593(7857):142-146. PMC: 9867906. DOI: 10.1038/s41586-021-03471-w. View

17.

Pouladzadeh M, Safdarian M, Eshghi P, Abolghasemi H, Bavani A, Sheibani B . A randomized clinical trial evaluating the immunomodulatory effect of convalescent plasma on COVID-19-related cytokine storm. Intern Emerg Med. 2021; 16(8):2181-2191. PMC: 8035885. DOI: 10.1007/s11739-021-02734-8. View

18.

Zhu N, Zhang D, Wang W, Li X, Yang B, Song J . A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020; 382(8):727-733. PMC: 7092803. DOI: 10.1056/NEJMoa2001017. View

19.

Yoon H, Bartash R, Gendlina I, Rivera J, Nakouzi A, Bortz 3rd R . Treatment of severe COVID-19 with convalescent plasma in Bronx, NYC. JCI Insight. 2021; 6(4). PMC: 7934933. DOI: 10.1172/jci.insight.142270. View

20.

Tremblay D, Seah C, Schneider T, Bhalla S, Feld J, Naymagon L . Convalescent Plasma for the Treatment of Severe COVID-19 Infection in Cancer Patients. Cancer Med. 2020; 9(22):8571-8578. PMC: 7537286. DOI: 10.1002/cam4.3457. View